Skip to content
Peptigraph home
Shop Peptides50% off*

Orforglipron for Heart Health: What the Evidence Shows

What human and animal studies show about Orforglipron for heart health, how strong that evidence is, and what is still unproven.

Medical review pendingOral small-molecule GLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
2
with an outcome for heart health, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for heart health, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
2
with an outcome for heart health

Evidence for heart health

Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Orforglipron for heart health: outcomes in published studies
OutcomeResultStudy typeSource
Cardiometabolic measuresWaist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol significantly improved versus placebo.Human RCTn = 3127The New England journal of medicine 2025, PMID 40960239
Blood pressure, lipids and hsCRPBlood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3 and hsCRP decreased significantly versus placebo (exploratory analysis).Human RCTn = 595Cardiovascular diabetology 2025, PMID 40481478

Orforglipron and heart health are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40960239

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Heart disease in plain terms

MedlinePlus calls heart disease the leading cause of death in the United States.[3]

Cardiometabolic measures

A pooled analysis of two phase 2 trials reported lower blood pressure, LDL cholesterol, triglycerides and hsCRP with orforglipron than placebo.[2]

The registry record for the obesity trial lists systolic blood pressure change for the pooled doses of orforglipron 6 mg, 12 mg and 36 mg.[4]

The record NCT05971940 registered change from baseline in non-HDL cholesterol.[5]

Heart-rate effect

In the semaglutide comparison, mean pulse rate rose 3.7 bpm on 12 mg and 4.7 bpm on 36 mg of orforglipron against 1.0 and 1.5 bpm with oral semaglutide.[6]

Other peptides people research for heart health

TirzepatideRetatrutideBPC-157TesamorelinSemaglutideHGHCagrilintideSS-31
All peptides for heart health, compared

Common questions

Does Orforglipron help with heart health?

The strongest study we summarise for heart health is human rct evidence, across 2 studies with an outcome for heart health. A trial result is not an approval; see the legal status.

Is Orforglipron approved for heart health?

Orforglipron is FDA approved (Foundayo, Apr 2026). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for heart health?

There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.

Is orforglipron good for the heart?

Trials show improvements in cardiovascular risk markers; none cited reports heart attacks or cardiovascular death outcomes.[2]

More on Orforglipron

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
  2. 2Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.Cardiovascular diabetology · 2025PMID 40481478Accessed 2 Oct 2026
  3. 3Official web pageOfficial web page · web page
  4. 4A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  5. 5A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  6. 6Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026

Found an error? Report a correction.